Alofisel for Crohn’s Fistulas Receives EMA Recommendation for Marketing Authorization in EU

Alofisel for Crohn’s Fistulas Receives EMA Recommendation for Marketing Authorization in EU
TiGenix received a European Medicines Agency (EMA) recommendation for the marketing authorization of Alofisel (darvadstrocel, Cx601) as an advanced therapy medicinal product (ATMP) for the treatment of complex perianal fistulas in people with Crohn’s disease. Perianal fistulas occur when an abnormal opening develops between the rectum and the outside of the body. It can lead to incontinence and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *